Erbitux 500 — Cetuximab 500 mg / 100 mL (1 Vial)
Erbitux (Cetuximab) is a highly effective antineoplastic drug from the group of monoclonal antibodies. It specifically targets the epidermal growth factor receptor (EGFR), which is present in excess on the surface of many cancer cells. By blocking this receptor, Erbitux interrupts the signaling pathways responsible for tumor growth, division, and survival, and prevents the formation of new blood vessels that nourish the neoplasm.
Manufacturer: Merck. The drug is a standard of targeted therapy for certain types of colorectal cancer, as well as head and neck cancer. Erbitux is often used in combination with chemotherapy or radiation therapy, significantly enhancing their therapeutic effect and helping to achieve control over the disease even in advanced stages.
Key Features:
- ✅ Targeted Selectivity: Binds only to cells expressing the EGFR receptor.
- ✅ Dual Mechanism: Not only blocks cell growth but also activates the body's immune system to attack the tumor (antibody-dependent cellular cytotoxicity).
- ✅ Synergy: Proven to increase the sensitivity of cancer cells to the effects of radiation and cytostatics.
Erbitux is prescribed by an oncologist for the treatment of the following diseases:
- 🔹 Metastatic Colorectal Cancer (Bowel Cancer): In patients with EGFR expression and absence of mutations in the RAS family genes (wild-type KRAS and NRAS genes).
- 🔹 Squamous Cell Carcinoma of the Head and Neck: In combination with radiation therapy for locally advanced forms, or in combination with chemotherapy for recurrent and metastatic cases.
Sales Form: 1 vial contains 500 mg / 100 ml of cetuximab solution (concentration 5 mg/ml).
⚠️ INSTRUCTIONS FOR USE:
- Administration Method: The drug is administered strictly intravenously via drip (infusion). Administration must be performed only by qualified medical personnel in a clinical setting.
- Dosage Regimen: The dose is calculated individually based on the patient's body surface area (m²). Usually, the first (loading) dose is higher than subsequent weekly doses.
- Premedication: Antihistamines and glucocorticosteroids are mandatory before each infusion to prevent allergic reactions.
- Infusion Rate: The first infusion is performed slowly (no more than 5 mg/min); subsequent infusions can be administered faster under condition monitoring.
- Storage: Strictly in the refrigerator at a temperature of 2°C to 8°C. Do not freeze!
- ⛔ Genetic Status: Presence of mutations in RAS genes (KRAS/NRAS) when treating colorectal cancer (in this case, the drug will not be effective).
- ⛔ Hypersensitivity: History of severe allergic reactions (grade 3 or 4) to cetuximab.
- ⛔ Pregnancy and Lactation: Use is contraindicated. Breastfeeding should be discontinued during treatment and for 2 months after the last dose.
- ⛔ Pediatric Use: Efficacy and safety in children under 18 years of age have not been established.
Erbitux therapy may be accompanied by specific reactions, which are often a sign of the drug's effectiveness:
- 🧪 Skin Reactions: Acne-like rash (most common), dry skin, itching, changes in nail structure. The appearance of a rash usually correlates with a good response to treatment.
- 🤒 Infusion Reactions: Fever, chills, dizziness, or shortness of breath during administration.
- 📉 Electrolyte Balance: Decreased blood magnesium levels (hypomagnesemia), less commonly — calcium. Regular biochemical blood analysis is required.
- 🤕 General: Fatigue, nausea, diarrhea, inflammation of the mucous membranes.
- ⚠️ Important: If serious skin lesions or signs of breathing difficulties appear, inform your doctor immediately for dose adjustment or prescription of supportive therapy.
What Customers Say
No reviews yet
Your review can be the first!